Video
Author(s):
Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.
Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
The OncFive: Top Oncology Articles for the Week of 12/8
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma